CASI Pharmaceuticals (CASIF) Debt to Equity (2021 - 2025)

CASI Pharmaceuticals has reported Debt to Equity for 5 years, with the latest figure at -$0.51 in Q4 2025.

• For the quarter ending Q4 2025, Debt to Equity fell 105.18% year-over-year to -$0.51; the trailing twelve-month figure through Dec 2025 stood at -$0.51 (down 105.18% YoY), and the FY2025 full-year result was -$0.51, down 105.18% from the prior year.
• Debt to Equity for Q4 2025 stood at -$0.51, down from $9.93 in the prior quarter.
• The five-year high for Debt to Equity was $781.92 in Q4 2023, with the low at -$0.51 in Q4 2025.
• Historically, Debt to Equity has averaged $113.57 across 5 years, with a median of $1.2 in 2024.
• Annual changes were most pronounced in 2023 — Debt to Equity surged 294740.74% — and 2025, when it plunged 105.18%.
• CASI Pharmaceuticals' Debt to Equity stood at $0.16 in 2021, then soared by 69.52% to $0.27 in 2022, then surged by 294740.74% to $781.92 in 2023, then sank by 98.73% to $9.93 in 2024, then tumbled by 105.18% to -$0.51 in 2025.
• The last three Debt to Equity figures came in at -$0.51 (Q4 2025), $9.93 (Q4 2024), and $2.05 (Q2 2024), per Business Quant data.